ADVENTRX Pharmaceuticals, Inc. announced today that it has submitted a New Drug Application(NDA) to the FDA for its product candidateANX-530 (vinorelbine injectable emulsion). “I congratulate our development team for achieving this importantmilestone on schedule in December, as planned. ANX-530 has the potential tooffer important benefits to cancer patients, and we look forward to workingwith FDA towards its approval,” said Brian M. Culley, Principal ExecutiveOfficer of ADVENTRX. “The ANX-530 NDA submission is a key step in our strategyto create valuable products that improve the performance of currently approveddrugs.” The company is seeking approval of ANX-530 for the same indications asNavelbine, a branded formulation of vinorelbine, including non-small celllung cancer. ADVENTRX submitted the NDA as a 505(b)(2) application, whichrelies in part on the FDA’s findings of safety and effectiveness of areference drug. The Company’s 505(b)(2) NDA submission includes data from oneclinical bioequivalence study designed to assess the pharmacokineticequivalence of ANX 530 and Navelbine, the reference drug.